Impacto en negocio

Generación de pipeline cualificado especialmente en marcado CE bajo MDR / IVDR, en desarrollo clínico y entrada en mercado USA

Presentación de servicios de consultoria regulatoria avanzada.

Reuniones B2B con empresas previamente identificadas y contactos generados in situ.

Análisis de tendencias sector

Alianzas estartégicas con partners teconlógicos

From idea to certified medical product - we help innovators bring safe, compliant, investable and scalable devices to market faster.

From idea to certified medical product - we help innovators bring safe, compliant, investable and scalable devices to market faster.

COOIDi Consultores aspira a posicionarse como una consultora líder en el ecosistema empresarial de la salud. Dado que su sede central se encuentra en Barcelona (Sant Cugat del Vallès), apoyamos a Catalonia.Health como uno de los clústeres de salud con mayor trayectoria y un importante punto de referencia para las empresas del sector de la salud y las ciencias de la vida en Cataluña.

COOIDi se une a todas aquellas empresas, emprendedores y entidades públicas o público-privadas dedicadas a crear nuevos productos, procesos y sistemas para posicionar a nuestro país como líder mundial.

El espíritu emprendedor y la innovación están presentes en nuestro ADN como empresa, y también entre nuestros valores como personas.

Estamos convencidos de que el compromiso de COOIDi con el Clúster Catalonia.Health nos ayudará a alcanzar nuestros objetivos y, al mismo tiempo, ayudará a todos los asociados del clúster a llevar a cabo todas y cada una de las acciones propuestas.

Catalonia.Health nos permitirá entrar en el sector, donde podremos aportar nuestro granito de arena para consolidar aún más la posición de liderazgo que ya ocupamos en el sector de la salud y las ciencias de la vida a nivel mundial.

Build relationships with HealthTech startups and investors, with a focus on sourcing early-stage opportunities and co-investment partnerships.

Collaborations, Offering Biotechnology R&D services, Offering Professionalservices and consulting.

CREATIO seeks collaborators to provide end-to-end support to bring their ATMPsto the clinic, and partners to co-developing ATMP-based solution.

I work at the front end of pharmaceutical development, engaging with customers early in their projects to help shape formulation and delivery strategies. I support applications across vaccines, injectables, and advanced drug delivery, working with solutions such as bioprocessing aids, vaccine adjuvants, specialty lipids, and phospholipids.

My role sits at the interface between commercial and technical teams, helping translate development challenges into practical solutions by connecting customers with the right excipients, technologies, and formulation expertise. I also support opportunities across the consumer health and veterinary markets, where formulation performance and differentiation are equally critical.

We aim to expand existing relationships and establish new ones with knowledge creators, such as research institutions, universities, and their technical teams, such as Innovation and Tech Transfer Offices, as well as early stage companies that are looking to create or furher develop their IP strategy and portfolio.

At Polar Nanopharma, Ecopol Tech Spin off, we are seeking for private investment and strategic partners to advance our oncology pipeline targeting highly heterogeneous and aggressive tumor settings with significant unmet medical need, including triple-negative breast cancer, non-small cell lung cancer and Lynch syndrome-associated cancers, the latter being developed in co-development with Hospital Clínic de Barcelona.

____________________________________________________________________________________________

🇪🇸 Polar NanoPharma, spin-off de Ecopol Tech, buscamos Inversión y socios estratégicos para avanzar nuestro pipeline oncológico dirigido a tumores altamente heterogéneos y agresivos con elevada necesidad médica no cubierta, incluyendo cáncer de mama triple negativo, cáncer de pulmón no microcítico y cánceres asociados al síndrome de Lynch, este último en co-desarrollo con el Hospital Clínic de Barcelona.

Seeking partners interested in licensing opportunities, co-development projects and tailor-made R&D programs, including custom formulation development, encapsulation of active ingredients, polymer design, analytical characterization and scale-up support in polymers and nanomedicines.

In parallel, Polar NanoPharma, a spin-off of Ecopol Tech focused on nanoparticle-based cancer therapies, is seeking funding and strategic investment partners to advance its oncology pipeline targeting highly heterogeneous and aggressive tumor settings with significant unmet medical need, including triple-negative breast cancer, non-small cell lung cancer and Lynch syndrome-associated cancers, the latter being developed in co-development with Hospital Clínic de Barcelona.

🇪🇸 ES

Ecopol Tech busca socios interesados en oportunidades de licencia, proyectos de co-desarrollo y programas de I+D a medida, incluyendo desarrollo de formulaciones personalizadas, encapsulación de ingredientes activos, diseño de polímeros, caracterización analítica y soporte al escalado en polímeros y nanomedicinas.

En paralelo, Polar NanoPharma, spin-off de Ecopol Tech centrada en terapias nanoparticuladas frente al cáncer, busca financiación y socios estratégicos de inversión para avanzar en su pipeline oncológico dirigido a tumores altamente heterogéneos y agresivos con elevada necesidad médica no cubierta, incluyendo cáncer de mama triple negativo, cáncer de pulmón no microcítico y cánceres asociados al síndrome de Lynch, este último en co-desarrollo con el Hospital Clínic de Barcelona.

Pre-coloured ABS plastics are widely used materials in external enclosures applications of medical devices.

Especially in parenteral drug de livery medical devices (medical devices designed to deliver a specific medicine to the patient through parenteral paths e.g. via mucosa (e.g. absorption through the lungs) or IV),  biocompatibility is a key property that needs to be complied to fulfil with medical regulations (e.g. EU MDR or US FDA regulatory requirements). Final medical devices must be tested according to ISO 10993 and it is the responsibility of the Medical OEM manufacturer to make sure that such tests are conducted and passed. Biocompatibility tests are expensive and there is the risk that the required medical device may not pass one or more of them. The implementation of specific production procedures like GMPs (Good Manufacturing Practices), clean rooms etc. is critical, but positive test results cannot be assured without the correct pre-selection of all materials needed to produce each component of the device.

In addition, medical device bright and intense colours are relevant for patients because they stimulate a positive attitude to take the drug medication, they help the distinction of different device part and facilitate the way how to use the device itself. They help to distinguish different types of drugs that are targeting to different types of diseases. Despite colour in medical device applications is such a key property, there are strict regulatory limitations in the type of pigments admitted in the colour formulations, and in their maximum allowed concentrations. When the biocompatibility requirement according to ISO 10993 must be met, not only the base ABS material must be biocompatible but also all the additives compounded with the material, including the colour formulation with all its different pigments. No biocompatible pigments must be directly excluded, and maximum allowed pigment concentrations must not be exceeded. Furthermore, special attention must be given to possible mutual interactions among different pigments, ABS material and other additives. ELIX Polymers eliminates those risks to OEMs, processors and developers providing a medical precoloured ABS material formulation that includes the complete colour recipe and does not need any further material modification. The complete formulation has been fully reviewed and pre-tested to meet biocompatibility according to ISO 10993 and other regulatory requirements. This is a much safer approach for medical OEMs and moulders instead of choosing a medical ABS in natural colour and compound it themselves with a masterbatch colour, during the injection   moulding process.